Elanco Animal Health Inc

Listed Company

ELANCIK 0001739104NYSELarge AcceleratedPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$4.71B

Net Income

$-232.00M

Total Assets

$13.36B

Equity

$6.55B

Shares Out

497.17M

Op. Cash Flow

$560.00M

Business

Elanco Animal Health Inc is a global animal health company that develops and delivers products and services to prevent and treat disease in pets and farm animals. It offers parasiticides, vaccines, therapeutics, medicated feed additives, injectable antibiotics, enzymes, insecticides and related services including veterinary consulting and contract manufacturing. The business operates as a single commercial segment organized around pet health and farm animal product categories with integrated R&D, manufacturing, regulatory and sales functions. Its products are marketed in more than 90 countries through veterinarians, third‑party distributors, retailers and e‑commerce channels.

Summary from filing dated 2025-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	4,715	4,439	4,417	4,411	4,764
Cost of sales	2,122	2,003	1,931	1,913	2,132
Gross Profit	2,593	2,436	2,486	—	—
Research and development	368	344	327	321	369
Marketing, selling and administrative	1,430	1,314	1,285	1,265	1,403
Amortization of intangible assets	543	527	548	528	556
Asset impairment, restructuring and other special charges	237	150	127	183	634
Goodwill impairment	0	0	1,042	0	0
Gain on divestiture	0	−640	0	0	—
Interest expense, net of capitalized interest	220	235	277	241	—
Other expense, net	19	18	75	32	—
(Loss) income before income taxes	−224	488	−1,195	−72	−571
Income tax expense	8	150	36	6	−88
Net (loss) income	−232	338	−1,231	−78	−483
Basic (usd per share)	−0.47	0.68	−2.5	−0.16	−0.99
Diluted (usd per share)	−0.47	0.68	−2.5	−0.16	−0.99
Basic (in shares)	496	494	492	488	487
Diluted (in shares)	496	497	492	488	487

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	545	468	352	345	638
Accounts receivable, net	873	805	842	797	833
Other receivables	67	81	168	205	195
Inventories	1,737	1,574	1,735	1,538	1,371
Prepaid expenses and other	236	287	310	394	237
Total current assets	3,458	3,215	3,407	3,279	3,274
Property and equipment, net	1,409	993	—	—	—
Goodwill	4,779	4,414	5,094	5,993	6,172
Other intangibles, net	3,408	3,681	4,494	4,842	5,587
Other noncurrent assets	304	311	341	378	390
Total assets	13,358	12,614	14,362	15,491	16,478
Accounts payable	368	296	270	390	416
Employee compensation	206	177	157	146	185
Sales rebates and discounts	416	332	367	324	319
Current portion of long-term debt and finance lease liability	74	44	—	—	—
Other current liabilities	533	466	409	454	433
Total current liabilities	1,597	1,315	1,241	1,702	1,647
Long-term debt and finance lease liability	3,943	4,277	—	—	—
Liability for sale of future revenue	304	0	—	—	—
Accrued retirement benefits	158	175	184	161	271
Deferred taxes	382	449	567	662	765
Other noncurrent liabilities	427	302	411	229	262
Total liabilities	6,811	6,518	8,139	8,202	8,970
Commitments and Contingencies	—	—	—	—	—
Preferred stock, 1,000,000,000 shares authorized, no par value; none issued	0	0	—	0	0
Common stock, 5,000,000,000 shares authorized, no par value; 496,975,154 and 494,445,839 shares issued and outstanding as of December 31, 2025 and 2024, respectively	0	0	0	0	0
Additional paid-in capital	8,870	8,817	8,777	8,738	8,696
Accumulated deficit	−2,182	−1,950	−2,288	−1,057	−979
Accumulated other comprehensive loss	−141	−771	−266	−392	−209
Total equity	6,547	6,096	6,223	7,289	7,508
Total liabilities and equity	13,358	12,614	14,362	15,491	16,478

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	680	662	694	682	716
Deferred income taxes	−134	−112	−80	−57	−148
Stock-based compensation expense	68	55	46	59	66
Asset impairment and write-down charges	71	81	32	81	345
Proceeds from interest rate swap settlements	0	5	57	207	0
Sold portion of royalty revenue	−19	0	0	—	—
Interest on liability for sale of future revenue	33	0	0	—	—
Other non-cash operating activities, net	−6	3	11	0	11
Receivables	−12	12	−40	14	−35
Inventories	−57	44	−160	−269	29
Other assets	21	11	−6	−109	25
Accounts payable and other liabilities	147	82	−94	−98	−116
Net Cash Provided by Operating Activities	560	541	271	452	483
Net purchases of property and equipment and software	−276	−147	−140	−171	−159
Cash paid for acquisitions	0	−41	−19	0	−342
Proceeds from divestitures	9	1,360	0	0	—
Other investing activities, net	−12	−14	−10	−8	9
Net Cash (Used for) Provided by Investing Activities	−279	1,158	−169	−179	−530
Proceeds from issuance of long-term debt	2,106	350	0	425	500
Repayments of long-term borrowings	−2,669	−1,600	−402	−677	−573
Proceeds from sale of future revenue, net of transaction costs	290	0	0	—	—
Other financing activities, net	−2	−17	−6	−32	−31
Net Cash Used for Financing Activities	−275	−1,492	−83	−549	210
Effect of exchange rate changes on cash and cash equivalents	71	−91	−12	−17	−31
Net increase in cash and cash equivalents	77	116	7	−293	132

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro